Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT02713672 |
| Other study ID # |
70-72600-98-005 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
February 23, 2016 |
| Last updated |
March 15, 2016 |
| Start date |
October 2014 |
| Est. completion date |
June 2015 |
Study information
| Verified date |
March 2016 |
| Source |
GGZ Centraal |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
The cytochrome P450 (CYP) is a group of metabolic enzymes, from which the 2D6 and CYP2C19
polymorphisms are specifically related to the metabolism of psychiatric drugs. The prevalence
of CYP2D6 and CYP2C19 polymorphisms differs among ethnicities. Depending on the number of
functional alleles, individuals are classified as Poor Metabolizer (PM), Intermediate
Metabolizer (IM), Extensive Metabolizer (EM) or Ultra Rapid Metabolizer (UM).
Research has suggested that PM genotype is a predisposing factor for antipsychotic-induced
side-effects. Besides susceptibility for side effects and lower quality of life, also, a
relationship between phenotype and costs of care has been shown.
Guidelines recommend that PM, IM and UM genotypes need dose adjustment, to optimize the
effectiveness of the drug and/or to reduce side effects. No research has been done to
investigate cost-effectiveness of implementation of genotyping in daily clinical psychiatric
practice.
This study investigates the effectiveness of implementation of CYP2D6 and CYP2C19 genotyping
in psychiatric patients in Curacao and analyzes the costs of genotyping versus health
benefits.
Description:
Subjects
This study is carried out on the Caribbean island Curacao and in the Netherlands. The
population (approx. 150,000 inhabitants) of Curacao is mainly of Negroid descent.
Participants were recruited from the Klinika Capriles, (the only psychiatric hospital on the
island) the psychiatric ward in the prison (FOBA) and the psychiatric polyclinic on the
island (Psychiaters Maatschap Antillen). The study protocol was approved by the Medical
Ethical Review Board (Maastricht) and study participants gave written informed consent after
explanation about the study.
Inclusion criteria were: (i) An Antillean ethnicity, defined in line with the Dutch Central
Bureau of Statistics as birth on the former Dutch Antilles and birth of at least one parent
on the former Dutch Antilles. (ii) Age 18 years or older. (iii) The use of an antipsychotic
or antidepressant and (iv) informed consent.
All the patients were genotyped and grouped according to predicted phenotype for CYP2D6 and
CYP2C19. Information about medication use was collected. Patients using CYP2D6 or CYP2C19
inhibiting medication according to Flockhart were selected. Enzyme activity scores of
patients using a strong inhibitor were multiplied by 0 which meant they converted
automatically to a PM phenotype. In patients using medium inhibitors, activity scores were
multiplied by 0.5. This is a widely used and accepted method.
All prescribed antipsychotics were calculated to a "Defined Daily Dose" (DDD) as defined by
the World Health Organization (WHO). For every patient the total equivalent of the DDD was
calculated. In this way it was possible to analyse if there were differences in total dose of
antipsychotics being used between the phenotype groups.
Patients who needed dose adjustment based on phenotype according to the Royal Dutch
Association for the Advancement of Pharmacy were selected.
Patients who were selected were matched with controls on gender, age and depot or oral
medication use. All participants received a 25 guilder gift token if they cooperated in the
study at both measuring points.
Assessments
Subjective experience, psychopathology, extrapyramidal side effects, quality of life, global
functioning and metabolic parameters were assessed at baseline (T0) and 4 months after dose
adjustment (T1). A medical doctor, trainee in psychiatry, blind for the intervention, was
responsible for all the measurements and was being trained in investigating extra pyramidal
side effects and measuring global functioning. Patients receiving depot medication were
measured in the same moment in the depot in T0 and T1.
Severity of patients' psychopathology was assessed with Brief Psychiatric Rating Scale
(BPRS), which measures 24 symptoms of psychiatric disease and is validated in Dutch 20.
Extrapyramidal symptoms were assessed with the St. Hans Ratings Scale (SHRS), which is a
multidimensional rating scale for the evaluation of hyperkinesia, parkinsonism, akathisia and
dystonia induced by neuroleptics. The dyskinesia is scored in two situations: in passive and
active circumstances.
Akathisia was being measured by the Barnes Rating Scale (BARS) for Drug-Induced Akathisia.
Subjective experience of the patients was measured with the Subjective Well-Being Under
Neuroleptics Scale (SWN-20), which is a 20- item, self-rating scale which assesses the
subjective experience over the preceding 7 days.
Quality of life was assessed with the EurolQol 5-D (EQ 5-D), which is a widely used rating
scale, that measures health status on five dimensions (mobility, self-care, usual activities,
pain/discomfort and anxiety/depression).
Global functioning was assessed with the World Health Organization Disability Assessment
Schedule 2.0 (WHODAS-36) 36 item proxy-administered version. The questionnaire measures
disability in 6 domains and was being administered by a personal care giver.
Metabolic parameters measured were blood pressure, Body Mass Index (BMI), waist size,
cholesterol, High Density Lipo-protein (HDL), Low Density Lipo-protein (LDL), triglycerides,
glucose, Hemoglobin A1c (HbA1C). Prolactin was also being measured. In patients receiving
antipsychotics metabolized by CYP2D6, plasma levels of antipsychotics were measured.
Procedures
After baseline measurements, another medical doctor, trainee in psychiatry made dose
adjustments according to guidelines of the Royal Dutch Association for the Advancement of
Pharmacy (KNMP) which was updated July 2013. Generally three options were available: 1.
Lowering/ enhancing the dose to 50-75% of the original dose 2. Prescription of medication not
being metabolized by CYP2D6 or CYP2C19 3. Stop CYP2D6 or CYP2C19 inhibiting medication.
A standard procedure for dose adjustments was being followed: Lowering the dose was done in
steps according to http://wiki.psychiatrienet.nl/index.php/SwitchAntipsychotics.
If an alternative antipsychotic had to be prescribed, first choice was flupentixol, second
choice olanzapine, third choice quetiapine. Inhibiting medication meant to tranquilize was
being replaced by benzodiazepines.
Complex cases were discussed with the research team and individual dose adjustment plans were
being made.
